Compare · head to head
Novartis vs Sol-Gel Technologies
Novartis ranks higher overall — 360 rank 38 vs 36.
Novartis leads on Quality (65 vs 42) and Safety (44 vs 37). Sol-Gel Technologies leads on Growth (42 vs 37) and Sentiment (63 vs 39).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Switzerland | Israel |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | XX-Large | X-Small |
| ISIN | CH0012005267 | IL0011417206 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 38 | 36 |
| Value | 51 | NR |
| Quality | 65 | 42 |
| Growth | 37 | 42 |
| Safety | 44 | 37 |
| Sentiment | 39 | 63 |
| Quality details | ||
| Profitability | 76 | 35 |
| Cash Truth | 55 | NR |
Novartis vs AstraZenecaNovartis vs DottikonNovartis vs BayerNovartis vs Hikma PharmaceuticalsAdd a third stock →
Full analyses: Novartis · Sol-Gel Technologies
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100